Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Aaron Shinkle

Interventional Pain Medicine Prattville, AL Medical Doctor

NPI 1497989180 CMS profile 1295690

660 McQueen Smith Rd N Ste E, Ste E, Prattville, AL 36066

Open in the dashboard

General payments

$8,588

380 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Aaron Shinkle of Prattville, AL is reported in the CMS Open Payments database as having received $8,588 across 380 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,258 48
2024 General $590 38
2023 General $615 36
2022 General $1,680 54
2021 General $2,467 98
2020 General $1,208 75
2019 General $771 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aaron Shinkle
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Aaron Shinkle were reported at $1,258. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Aaron Shinkle Interventional Pain Medicine median Middle half National median
2019 $771 $684 $216–$2,079 $163
2020 $1,208 $382 $122–$1,109 $114
2021 $2,467 $552 $167–$1,554 $132
2022 $1,680 $605 $187–$1,924 $149
2023 $615 $671 $195–$1,915 $160
2024 $590 $684 $206–$1,837 $164
2025 $1,258 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $5,277 209 payments
  2. Collegium Pharmaceutical, Inc. $950 69 payments
  3. Boston Scientific Corporation $607 19 payments
  4. Scilex Pharmaceuticals Inc. $222 14 payments
  5. Amgen Inc. $211 7 payments
  6. Arbor Pharmaceuticals, Inc. $189 9 payments
  7. Forte Bio-Pharma LLC $177 4 payments
  8. Biodelivery Sciences International, Inc. $121 6 payments
  9. Nevro Corp. $115 4 payments
  10. Stimwave Technologies Incorporated $72 2 payments
  11. Other $648 37 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,588 380 payments
Products named General payments · program years 2019–2025
  1. PROCLAIM Neuromodulation $1,469 54 payments
  2. Proclaim Family of SCS IPGs $1,114 53 payments
  3. Proclaim IPG $1,087 43 payments
  4. PROCLAIM Structural Heart $529 20 payments
  5. XTAMPZA $470 43 payments
  6. BELBUCA $452 23 payments
  7. ETERNA $395 10 payments
  8. Prodigy Family of SCS IPGs $252 3 payments
  9. AIMOVIG $232 8 payments
  10. ARTISAN $208 4 payments
  11. Other $3,058 135 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

24,503

Median for Anesthesiology: 322

Drug cost

$877,165

Median for Anesthesiology: $8,738

Branded share of claims

46.7%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Belbuca Buprenorphine Hcl Brand 276 $211,206
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 5,105 $82,970
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 4,330 $82,400
Oxycontin Oxycodone Hcl Brand 109 $72,774
Buprenorphine Generic 214 $62,212
Pregabalin Generic 2,068 $46,528
Gabapentin Generic 3,870 $46,146
Xtampza Er Oxycodone Myristate Brand 73 $42,255
Relistor Methylnaltrexone Bromide Brand 15 $31,452
Ozempic Semaglutide Brand 25 $24,225

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$903,478

Of which drugs: $24,772

Medicare patients

873

Average age 71

Services billed

87,902

509 women, 364 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 36%
Ischemic heart disease 36%
Depression 27%
Chronic kidney disease 26%
COPD 22%
Heart failure 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 410 70,753 $7,061
Injection, methylprednisolone acetate, 80 mg J1040 Office 244 292 $2,090
Injection, midazolam hydrochloride, per 1 mg J2250 Office 325 2,214 $228
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 173 2,352 $207
Injection, ketorolac tromethamine, per 15 mg J1885 Office 67 167 $81

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BELBUCA
  • Collegium Pharmaceutical, Inc. $146
$146 276 —
ZTLido
  • Scilex Pharmaceuticals Inc. $38
$38 — —
Lucemyra
  • USWM, LLC $27
$27 — —
PROLATE
  • Forte Bio-Pharma LLC $13
$13 — —
NALOCET
  • Forte Bio-Pharma LLC $3
$3 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

380 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record